This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

DaVita Clinical Research Presents Research Results At The 33rd Annual Dialysis Conference

DaVita Clinical Research ® (DCR ®), a specialty contract research organization with services spanning the full spectrum of drug and device development, presented research results at the 33rd Annual Dialysis Conference (ADC) in Seattle, March 9-12, 2013.

This international conference has become an influential annual meeting in the dialysis and nephrology communities. The 2012 meeting attracted over 1,800 participants from more than 40 countries.

Researchers from DaVita ®, the dialysis division of DaVita Healthcare Partners Inc., and DCR presented results from a number of innovative clinical improvement programs originating from DaVita and its research partners. DCR provides a collaborative bridge between DaVita’s health care community and the academic, pharmaceutical and biotech research community. DCR and DaVita share a dedication to improving the health and quality of life for kidney care patients.

“Our goal at DaVita is to try to improve our patients’ quality of life. Research is a critical vehicle to achieve that end,” said Mahesh Krishnan, M.D., M.P.H., M.B.A., F.A.S.N., vice president of clinical research. “The work presented at ADC is intended to lead to better clinical outcomes and better quality of life for chronic kidney disease and end-stage renal disease patients around the world.”

ADC featured the following oral presentations by John Moran, M.D., F.A.C.P., vice president of medical affairs at DaVita:
  • Urgent-Start Peritoneal Dialysis: A Clinical Process Improvement Report – Monday, March 11. Slide Forum IV, Clinical Studies & Experiences Part B.
  • Implementation of Alcayis Protocol Markedly Improves Peritonitis Rates – Monday, March 11. Slide Forum IV, Clinical Studies & Experiences Part B.
  • Decreasing Peritonitis Rate in PD Resulting in Lower Mortality and Technique Failure – Monday, March 11. Slide Forum I, Quality Improvement.

ADC also featured the following poster presentation:
  • Association of Pruritis and Quality of Life (QOL) Among Patients at a Large Dialysis Provider (Bond TC, Mutell R, Wilfehrt HM, and Krishnan M.) – Sunday, March 10. Poster Forum I, Quality Improvement.

DaVita, DaVita Clinical Research, DCR and DaVita HealthCare Partners are trademarks or registered trademarks of DaVita Healthcare Partners Inc. All other trademarks are the property of their respective owners.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.78 0.05%
FB $118.64 0.90%
GOOG $700.18 1.00%
TSLA $242.81 0.85%
YHOO $36.56 -0.12%


Chart of I:DJI
DOW 17,883.18 +109.54 0.62%
S&P 500 2,080.08 +14.78 0.72%
NASDAQ 4,812.1680 +36.81 0.77%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs